{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:42Z","timestamp":1789240002135,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clinthera.2025.12.017","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:26:20Z","timestamp":1769516780000},"page":"247-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Profiling of Potential Postmarket Risk Tracking and Pharmacovigilance Data for Avacopan"],"prefix":"10.1016","volume":"48","author":[{"given":"Zhilan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoni","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.12.017_bib0001","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MED.0b013e3282f15407","article-title":"Glucocorticoid-induced osteoporosis","volume":"14","author":"Berris","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/mr\/roac037","article-title":"Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: a subanalysis of a randomized phase 3 study","volume":"33","author":"Harigai","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103910","article-title":"The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis","volume":"24","author":"Michailidou","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10238-024-01457-2","article-title":"Characteristic changes in the mRNA expression profile of plasma exosomes from patients with MPO-ANCA-associated vasculitis and its possible correlations with pathogenesis","volume":"24","author":"Chen","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0006","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.autrev.2012.10.019","article-title":"p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris","volume":"12","author":"Mavropoulos","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0007","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virusres.2018.05.028","article-title":"Role of MAPK\/MNK1 signaling in virus replication","volume":"253","author":"Kumar","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0009","first-page":"100","article-title":"MAPK is implicated in sepsis, immunity, and inflammation","volume":"8","author":"Saggini","year":"2024","journal-title":"Int J Infect"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0010","first-page":"46","article-title":"Inhibition of PI3K\u03b2 and mTOR influence the immune response and the defense mechanism against pathogens","volume":"7","author":"Avivar-Valderas","year":"2023","journal-title":"International Journal of Infection"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0011","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.3390\/ijms23137353","article-title":"Immunomodulatory properties of PI3K\/AKT\/mTOR and MAPK\/MEK\/ERK inhibition augment response to immune checkpoint blockade in melanoma and triple-negative breast cancer","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0012","first-page":"756","article-title":"Current understanding of the pathogenesis of ANCA-associated vasculitis and novel treatment options targeting complement activation","volume":"15","author":"Drouzas","year":"2025","journal-title":"Life (Basel)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910673","article-title":"C5a induces inflammatory signaling and apoptosis in PC12 cells through C5aR-dependent signaling: a potential mechanism for adrenal damage in sepsis","volume":"25","author":"Mrozewski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0015","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s10571-022-01275-8","article-title":"Mild hypothermia alleviates complement C5a-induced neuronal autophagy during brain ischemia-reperfusion injury after cardiac arrest","volume":"43","author":"Wang","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200812-1928OC","article-title":"C5a mediates peripheral blood neutrophil dysfunction in critically ill patients","volume":"180","author":"Conway Morris","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0017","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.cell.2023.04.031","article-title":"C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection","volume":"186","author":"Desai","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102829","article-title":"Vasculitis therapy refines vasculitis mechanistic classification","volume":"20","author":"Torp","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13878","article-title":"A phase I thorough QT\/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants","volume":"17","author":"Miao","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami","year":"2025","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0022","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1096\/fj.15-271635","article-title":"Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin","volume":"29","author":"Russkamp","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0023","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/medicina61071205","article-title":"Targeting the roots of kidney disease: systematic review of the therapies targeting the complement system","volume":"61","author":"Roman","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0024","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","article-title":"Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Patel","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0026","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70001","article-title":"Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials","volume":"7","author":"Merkel","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005743","article-title":"Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide","volume":"11","author":"Geetha","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0029","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s41927-025-00555-2","article-title":"Avacopan is effective in inducing remission for MPA\/GPA, regardless of changes in serum C5a levels: a single-center study in Japan","volume":"9","author":"Ushio","year":"2025","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15400","article-title":"Case report: avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia","volume":"27","author":"Kioi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0032","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0033","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0034","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40360-025-00890-7","article-title":"A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)","volume":"26","author":"Xue","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0036","unstructured":"U.S.FDA Adverse Event Reporting System\uff08FAERS\uff09Database. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed April 9, 2025."},{"key":"10.1016\/j.clinthera.2025.12.017_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0038","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0039","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0040","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1038\/s41598-025-92741-y","article-title":"Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0041","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","article-title":"Mechanisms and consequences of sex differences in immune responses","volume":"20","author":"Dunn","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0042","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13293-023-00495-x","article-title":"Sex differences in the percentage of IRF5 positive B cells are associated with higher production of TNF-\u03b1 in women in response to TLR9 in humans","volume":"14","author":"Beisel","year":"2023","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12017-025-08875-9","article-title":"Equol as a multitarget agent against neurodegeneration: mechanistic insights into its molecular modulation","volume":"27","author":"Jahan","year":"2025","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.986840","article-title":"Consequences of sex differences in type I IFN responses for the regulation of antiviral immunity","volume":"13","author":"Pujantell","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0046","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18490","article-title":"Sex hormones in COVID-19 severity: the quest for evidence and influence mechanisms","volume":"28","author":"Xiao","year":"2024","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrneph.2017.181","article-title":"Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease","volume":"14","author":"Carrero","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107422","article-title":"STIM1-dependent store-operated calcium entry mediates sex differences in macrophage chemotaxis and monocyte recruitment","volume":"300","author":"Fresquez","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0049","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2042-6410-4-16","article-title":"Sex and inflammation in respiratory diseases: a clinical viewpoint","volume":"4","author":"Casimir","year":"2013","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0050","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0051","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2019.08.010","article-title":"Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials","volume":"121","author":"Davidson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0052","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","article-title":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors","volume":"16","author":"Kao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0053","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1093\/rheumatology\/keaf122","article-title":"Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial","volume":"64","author":"Geetha","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0054","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2215\/CJN.00480115","article-title":"Outcome and treatment of elderly patients with ANCA-associated vasculitis","volume":"10","author":"Weiner","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/RHU.0b013e31816b2fbd","article-title":"ANCA vasculitis in the elderly","volume":"14","author":"Hoganson","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0056","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/rheumatology\/keae534","article-title":"The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain","volume":"64","author":"Draibe","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0057","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s13730-025-00965-8","article-title":"Successful use of avacopan in a case of ANCA-associated vasculitis with treatment-resistant medium-sized vessel involvement","volume":"14","author":"Tsuchiya","year":"2025","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0058","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/mrcr\/rxae071","article-title":"Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: a rare case of liver biopsy in the chronic phase of liver injury","volume":"9","author":"Yamaguchi","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0059","article-title":"Alopecia areata: pathogenesis, diagnosis, and therapies","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0060","first-page":"112","article-title":"Structural and functional effects of C5aR1 antagonism in a rat model of neonatal hypoxic-ischemic encephalopathy","volume":"47","author":"Saadat","year":"2025","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0061","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s13555-025-01471-6","article-title":"Meta-analysis of gene expression reveals the core transcriptomic profile of lesional scalp in alopecia areata","volume":"15","author":"Rivera-Ruiz","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0062","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s13555-025-01517-9","article-title":"Evaluating current and emergent jak inhibitors for alopecia areata: a narrative review","volume":"15","author":"Sanchez","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0063","doi-asserted-by":"crossref","first-page":"69","DOI":"10.47936\/encephalitis.2024.00017","article-title":"The relationship between sleep and innate immunity","volume":"4","author":"Lee","year":"2024","journal-title":"Encephalitis"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0064","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.2174\/138161208786549281","article-title":"The role of cytokines in sleep regulation","volume":"14","author":"Krueger","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1486548","article-title":"Interference between immune cells and insomnia: a bibliometric analysis from 2000 to 2023","volume":"16","author":"Tang","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0066","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/biom10010137","article-title":"Microglia mediated neuroinflammation: focus on PI3K modulation","volume":"10","author":"Cianciulli","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0067","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241278498","article-title":"Adverse event profiles of CDK4\/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system","volume":"15","author":"Shen","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0068","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.fmre.2022.04.016","article-title":"Dock4 is required for the maintenance of cochlear hair cells and hearing function","volume":"3","author":"Hong","year":"2023","journal-title":"Fundam Res"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.gep.2024.119356","article-title":"Gene expression analysis of oxidative stress-related genes in the apical, middle, and basal turns of the cochlea","volume":"51","author":"Yang","year":"2024","journal-title":"Gene Expr Patterns"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0071","first-page":"26","article-title":"ANCA-associated glomerulonephritis: diagnosis and therapy proceedings of the Henry Shavelle lectureship","volume":"5","author":"Ivkovi\u0107","year":"2025","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0072","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11795","article-title":"Treatment with avacopan in patients with respiratory tract manifestations of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Specks","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0073","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/DDDT.S341842","article-title":"Evaluating avacopan in the treatment of ANCA-associated vasculitis: design, development and positioning of therapy","volume":"19","author":"van Leeuwen","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0074","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ekir.2023.11.005","article-title":"Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy","volume":"9","author":"\u0218tefan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2025.12.017_bib0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1681\/ASN.0000000631","article-title":"Why is C5a inflammatory complement inhibition not enough to improve C3 glomerulopathy?","volume":"36","author":"Zipfel","year":"2025","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825004515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:07:36Z","timestamp":1774620456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825004515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0149291825004515"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling of Potential Postmarket Risk Tracking and Pharmacovigilance Data for Avacopan","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}